PharmaEssentia’s Besremi receives FDA approval for ET

The US FDA has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET). The approval is based on data from the global Phase III SURPASS ET trial, demonstrating durable ELN responses and control. Besremi may be prescribed for adults with ET regardless of genotype or disease status. Credit: 89stocker / Shutterstock.com. The US Food and Drug Administration (FDA) has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET). This marks the first FDA-approved treatment for ET in nearly 30 years. LOA and PTSR Model Eftilagimod Alfa in Human Epidermal Growth Fac... Reports LOA…

Source: Pharmaceutical Technology